Consano Bio to Highlight C-1101, Its Potential First-in-Class Disease-Modifying Therapeutic for Chronic Sciatica, at Upcoming October Conferences

BURLINGTON, Mass., Oct. 8, 2026 /PRNewswire/ -- Consano Bio, Inc., a clinical-stage biotechnology company advancing novel therapeutics designed to address serious, painful orthopedic conditions, today announced that management will participate in two upcoming industry conferences to highlight C-1101, the company's novel, platelet-derived multi-protein biologic therapeutic designed to treat lumbosacral radiculopathy (LSR), or chronic sciatica.

On October 15, 2026, Consano Bio will present at Align Summit, MassBio's annual partnering conference, in Boston, MA, and on October 28, 2026, management will participate in a panel discussion at the BioFuture conference in New York, NY.

Details are as follows:

During each conference, management will meet with registered investors and potential partners to present Consano Bio's business and clinical development strategy, highlight recent corporate achievements, and discuss anticipated milestones.

About Chronic Lumbosacral Radiculopathy (LSR)

Chronic, painful LSR, or chronic sciatica, is a chronic lower back pain condition caused by damage or irritation of spinal nerve roots in the lower back, leading to radiating pain, numbness, and weakness from the spine into the leg. There are no FDA-approved pharmaceutical treatments for chronic sciatica despite its prevalence and widespread societal and economic impact.

About C-1101

C-1101 is Consano Bio's lead investigational clinical candidate and the first pharmaceutical therapy of its kind in development: a novel, platelet-derived multi-protein biologic therapeutic. It is designed to treat LSR, or chronic sciatica, by modulating inflammation and stimulating and enhancing cellular repair at the site of injury. The product contains consistent concentrations of cytokines, growth factors, and matrix proteins designed to help trigger the body's natural healing response. Delivered via an epidural injection, C-1101 is intended to provide supraphysiologic concentrations of these proteins directly to the site of nerve injury.

About Consano Bio

Consano Bio is a clinical-stage biotechnology company dedicated to transforming the treatment of painful and debilitating orthopedic conditions through a new class of multi-protein biologic therapeutics. The company is headquartered in the Greater Boston area. For more information, visit www.consanobio.com.

Contacts: 

Consano Bio

Rahul Bansal

VP, Finance & Investor Relations

rbansal@consanobio.com

(908) 230-6689

Investor Relations

Tiberend Strategic Advisors, Inc.

David Irish

(231) 632-0002

dirish@tiberend.com 

Media Relations

Tiberend Strategic Advisors, Inc.

Casey McDonald

(646) 577-8520

cmcdonald@tiberend.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/consano-bio-to-highlight-c-1101-its-potential-first-in-class-disease-modifying-therapeutic-for-chronic-sciatica-at-upcoming-october-conferences-302901769.html

SOURCE Consano Bio